Charles River Laboratories Intl. Inc vs SYSCO Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $228.01 (market cap $11.14B), while SYSCO Corporation trades at $82.02 (market cap $39.62B). The key difference: SYSCO Corporation is far larger — about 3.6× Charles River Laboratories Intl. Inc's market cap, and SYSCO Corporation pays a 2.66% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SYY | |
|---|---|---|
Market Cap | $11.14B | $39.62B |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $91.16 |
52-Week Low | $145.57 | $69.30 |
Enterprise Value | $14.00B | $53.10B |
Dividend Yield | — | 2.66% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Sysco Corporation (SYY) trades at $83.46, down 0.44% on the day, with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with consistent revenue growth reaching $81.37B in 2025 and a net income margin of 2.08%. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. The company maintains solid cash flow generation and recently announced a $0.55 dividend payable in July 2026.
Sysco's outlook remains favorable with 60% analyst buy ratings and a consensus price target of $83.67, slightly above current levels. Key opportunities include sustained revenue growth and operational efficiencies, while risks involve margin pressure and competitive industry dynamics. The stock presents a balanced investment case with moderate upside potential amid stable cash flows.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →